IRIS UniCatt

Papa, Alfredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.217
EU - Europa 4.601
AS - Asia 4.284
SA - Sud America 992
AF - Africa 114
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 2
Totale 15.221
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.063
SG - Singapore 1.973
DE - Germania 1.606
CN - Cina 1.266
BR - Brasile 805
SE - Svezia 760
IT - Italia 468
UA - Ucraina 396
FR - Francia 324
GB - Regno Unito 265
IE - Irlanda 212
VN - Vietnam 208
IN - India 170
ID - Indonesia 167
FI - Finlandia 165
RU - Federazione Russa 121
CA - Canada 90
TR - Turchia 82
AR - Argentina 75
PL - Polonia 66
JP - Giappone 60
BD - Bangladesh 55
HK - Hong Kong 49
KR - Corea 48
BE - Belgio 43
EC - Ecuador 38
IQ - Iraq 36
MX - Messico 35
ZA - Sudafrica 35
IR - Iran 31
ES - Italia 27
NL - Olanda 27
AT - Austria 26
VE - Venezuela 21
CO - Colombia 17
PK - Pakistan 17
SA - Arabia Saudita 17
LT - Lituania 15
AE - Emirati Arabi Uniti 13
CI - Costa d'Avorio 12
CZ - Repubblica Ceca 12
MA - Marocco 12
IL - Israele 11
JO - Giordania 11
RO - Romania 11
TN - Tunisia 10
CL - Cile 9
EG - Egitto 9
AZ - Azerbaigian 8
DZ - Algeria 8
EU - Europa 8
HU - Ungheria 8
JM - Giamaica 8
UY - Uruguay 8
UZ - Uzbekistan 8
KE - Kenya 7
OM - Oman 7
PY - Paraguay 7
BG - Bulgaria 6
CH - Svizzera 6
CR - Costa Rica 5
NP - Nepal 5
PE - Perù 5
CG - Congo 4
EE - Estonia 4
GR - Grecia 4
KZ - Kazakistan 4
LV - Lettonia 4
AL - Albania 3
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
BZ - Belize 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
LA - Repubblica Popolare Democratica del Laos 3
MN - Mongolia 3
PA - Panama 3
PH - Filippine 3
PT - Portogallo 3
RS - Serbia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
CY - Cipro 2
GE - Georgia 2
GY - Guiana 2
KG - Kirghizistan 2
KW - Kuwait 2
LB - Libano 2
LK - Sri Lanka 2
LY - Libia 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
NG - Nigeria 2
Totale 15.193
Salva come PNG Salva come JPEG
Città #
Chandler 921
Singapore 886
Ashburn 498
Jacksonville 256
Beijing 219
New York 216
Dublin 206
San Mateo 191
Hangzhou 173
Hefei 154
Los Angeles 152
Jakarta 150
Ann Arbor 127
Boston 119
Nanjing 115
Dearborn 111
Wilmington 110
Munich 106
Nürnberg 92
Milan 91
Cattolica 82
Dallas 73
Ho Chi Minh City 73
Princeton 72
Frankfurt am Main 71
Moscow 69
São Paulo 62
Marseille 54
Houston 52
Helsinki 49
Izmir 48
Redwood City 48
Hong Kong 47
Nanchang 46
Bremen 45
Rome 45
Seoul 43
Hanoi 42
Lawrence 42
Tokyo 42
Brussels 41
Redmond 41
Chicago 38
Kent 38
The Dalles 38
Woodbridge 37
Boardman 36
Seattle 36
Warsaw 35
Buffalo 34
Montreal 30
Brooklyn 29
Fairfield 28
London 27
Changsha 26
Norwalk 26
Stockholm 26
Kunming 25
Rio de Janeiro 25
Santa Clara 25
Turku 25
Kraków 24
San Francisco 24
Augusta 23
Hebei 23
Shanghai 23
Toronto 23
Denver 22
Nuremberg 22
Shenyang 22
Trieste 22
Belo Horizonte 21
Andover 20
Lancaster 20
Mountain View 20
Phoenix 20
Pune 20
Detroit 19
Poplar 19
Guangzhou 18
Jiaxing 18
Tianjin 18
Atlanta 17
Baghdad 17
Chennai 17
Kish 17
Lappeenranta 17
North Bergen 17
Düsseldorf 16
Leawood 16
Johannesburg 15
Manchester 15
Vienna 15
Washington 14
Brasília 13
Portsmouth 13
University Park 13
Abidjan 12
Bogotá 12
Curitiba 12
Totale 7.373
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 353
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. 225
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 194
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 190
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 186
Early atherosclerosis in patients with inflammatory bowel disease. 184
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 184
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 180
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 179
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 176
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 173
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 173
Assessment of neurological manifestations in hospitalized patients with COVID-19 172
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis 168
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 161
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 157
Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD) 156
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 156
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 156
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 154
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease 154
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 152
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 148
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 141
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 139
Use of infliximab in particular clinical settings: management based on current evidence. 137
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 136
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease 133
-Extraintestinal manifestations in inflammatory Bowel disease. 132
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 132
A) Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? 127
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 127
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 127
Development and validation of predictive assessment of complicated diverticulitis score 127
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 126
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 126
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 125
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 124
Effect of moderate and heavy alcohol consumption on intestinal transit time 121
A novel pathogenic role for microvasculature in inflammatory bowel disease. 118
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 117
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 115
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 115
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 115
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 113
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 112
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 110
Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. 109
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 108
Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events 108
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. 108
A) Platelets: new players in the mucosal scenario of inflammatory bowel disease. 107
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 106
Biological therapies for inflammatory bowel disease: research drives clinics. 104
Differentiation affects the release of exosomes from colon cancer cells and their ability to modulate the behavior of recipient cells 103
Can we predict the efficacy of anti-TNF-α agents? 103
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 102
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 101
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 100
A) Review article: inherited thrombophilia in inflammatory bowel disease. 97
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 96
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 95
Mucosal healing in ulcerative colitis: surveillance or colectomy? 94
Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells 94
Crohn's Disease: Radiological Answers to Clinical Questions and Review of the Literature 93
How to face the advent of sars-cov-2 vaccination in ibd patients: Another task for gastroenterologists 93
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 92
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 92
Radiomics could predict surgery at 10 years in Crohn's disease 91
Hot topics in surgical management of acute diverticulitiss 91
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease 91
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease 91
-Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation 90
Cytomegalovirus Infection: An Underrated Target in Inflammatory Bowel Disease Treatment 88
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. 88
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 88
Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative Colitis 88
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 87
New therapeutic approach in inflammatory bowel disease. 87
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 87
Microbiota Composition in Diverticular Disease: Implications for Therapy 86
Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. 86
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 86
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 84
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools 83
Microbiota Composition in Diverticular Disease: Implications for Therapy 82
Gut dysbiosis-related thrombosis in inflammatory bowel disease: Potential disease mechanisms and emerging therapeutic strategies 82
Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells 82
Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery 82
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 81
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 80
The Role of Microbiota in Pancreatic Cancer 79
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 78
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 78
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 78
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 78
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 77
Role of Helicobacter pylori CagA+ infection in determining oxidative DNA damage in gastric mucosa 77
Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. 77
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 76
Totale 11.910
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.263
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.263
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021451 0 0 0 0 0 23 93 24 96 20 176 19
2021/20221.060 63 78 21 111 47 21 12 214 38 68 168 219
2022/20232.307 299 297 157 418 135 301 88 188 263 45 74 42
2023/20241.230 57 319 53 70 42 174 68 43 45 77 135 147
2024/20252.679 60 88 249 68 238 81 111 124 329 286 570 475
2025/20264.080 1.104 241 442 866 1.205 222 0 0 0 0 0 0
Totale 15.389